001434366 000__ 06620cam\a2200553\i\4500
001434366 001__ 1434366
001434366 003__ OCoLC
001434366 005__ 20230309003725.0
001434366 006__ m\\\\\o\\d\\\\\\\\
001434366 007__ cr\cn\nnnunnun
001434366 008__ 210226s2021\\\\sz\\\\\\ob\\\\001\0\eng\d
001434366 019__ $$a1240586087$$a1253403709
001434366 020__ $$a9783030683344$$q(electronic bk.)
001434366 020__ $$a3030683346$$q(electronic bk.)
001434366 020__ $$a9783030683351$$q(print)
001434366 020__ $$a3030683354
001434366 020__ $$z3030683338
001434366 020__ $$z9783030683337
001434366 0247_ $$a10.1007/978-3-030-68334-4$$2doi
001434366 035__ $$aSP(OCoLC)1239962687
001434366 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dYDXIT$$dOCLCO$$dGW5XE$$dEBLCP$$dOCLCF$$dN$T$$dVT2$$dLIP$$dUKAHL$$dOCLCQ$$dOCLCO$$dOCLCQ
001434366 049__ $$aISEA
001434366 050_4 $$aRC270.8$$b.C35 2021
001434366 08204 $$a616.99/406$$223
001434366 1001_ $$aCavalcanti, Iago Dillion Lima,$$eauthor.
001434366 24510 $$aAdvances in cancer treatment :$$bfrom systemic chemotherapy to targeted therapy /$$cIago Dillion Lima Cavalcanti, José Cleberson Santos Soares.
001434366 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2021]
001434366 300__ $$a1 online resource
001434366 336__ $$atext$$btxt$$2rdacontent
001434366 337__ $$acomputer$$bc$$2rdamedia
001434366 338__ $$aonline resource$$bcr$$2rdacarrier
001434366 347__ $$atext file
001434366 347__ $$bPDF
001434366 504__ $$aIncludes bibliographical references and index.
001434366 5050_ $$aIntroduction -- Cancer: concepts and epidemiology -- A brief history of cancer -- What is Cancer? -- Cancer Epidemiology -- Cancer development and immunology -- Cell cycle -- Cell cycle control: the function of cyclins -- Cancer triggering agents -- Proto-oncogenes -- Tumor suppressor genes -- Development of tumor mass -- Cancer Immunology -- Discovery of tumor markers -- Cancer diagnosis -- Impact of the discovery of tumor markers -- Main tumor markers for cancer diagnosis -- Alpha-fetoprotein (AFP) -- Human Chorionic Gonadotropin (SHCG) -- Mucin-like cancer-associated antigen (MCA) -- CA 15.3 -- Carcinoembryonic antigen (CEA) -- Bladder tumor antigen (BTA) -- Telomerase -- Nuclear matrix protein (NMP 22) -- Cyfra 21.1 -- Prostatic acid phosphatase (PAP) -- Prostate-specific antigen (PSA) -- CA 125 -- CA 19.9 -- p53 -- CA 72.4 -- K-ras -- HER2 -- Cancer staging -- Conventional cancer treatment -- Therapeutic modalities of cancer -- Surgery -- Radiotherapy -- Antineoplastic chemotherapy -- Classification of antineoplastic agents by cycle -- Specific cycle antineoplastics -- Nonspecific antineoplastic agents -- Classification of antineoplastic agents by chemical structure and function -- Alkylating agents -- Antimetabolites -- Plant-derived antineoplastics -- Antitumor antibiotics -- Chemotherapy toxicity -- Hematological toxicity -- Liver toxicity -- Cardiac toxicity -- Anthracyclines -- Fluoropyrimidine -- Taxanes -- Pulmonary toxicity -- Neurological toxicity -- Renal toxicity -- Gastrointestinal toxicity -- Metabolic changes -- Targeted therapies in cancer treatment -- Overexpressed receptors on tumor cells -- Immunotherapy -- Monoclonal antibodies -- Types of monoclonal antibodies -- Side effects of monoclonal antibodies -- Checkpoint Inhibitors -- Side effects of checkpoint inhibitors -- Cancer Vaccines -- Vaccines in cancer prevention -- Vaccines for the treatment of cancer -- Non-specific immunotherapies -- Tyrosine kinase inhibitors -- Imatinib -- Gefitinib -- Erlotinib -- Sorafenib -- Dasatinib -- Nilotinib -- Lapatinib -- Adverse events of tyrosine kinase inhibitors -- Conventional chemotherapy vs. targeted therapy -- Differences between conventional chemotherapy and targeted therapy -- Risks and benefits of conventional chemotherapy compared to targeted therapy -- Eligibility criteria for the indication of the targeted therapy -- Side effects of targeted therapy -- Can targeted therapy replace conventional chemotherapy? -- Targeted therapy associated with conventional chemotherapy -- Pharmaceutical nanotechnology applied to cancer -- Pharmaceutical nanotechnology -- Classification of nanosystems -- Liposomes -- Micelles -- Polymeric nanoparticles -- Solid lipid nanoparticles -- Magnetic nanoparticles -- Metal nanoparticles -- Main functions of nanosystems in cancer -- Pharmaceutical nanotechnology in cancer diagnosis -- Pharmaceutical nanotechnology for cancer treatment.
001434366 506__ $$aAccess limited to authorized users.
001434366 520__ $$aThis work covers the pathophysiology of cancer, exploring the difficulty of optimal treatment due to the complexity and diversity of cancer types. The search for distinctive molecular biology characteristics of tumor cells is especially relevant in the identification of overexpressed receptors and proteins that can be used as a target for cancer treatment. We highlight the main therapeutic modalities, particularly conventional systemic chemotherapy, addressing its mechanisms of action, therapeutic classes and even the toxic effects. We also describe the main tumor markers, their importance in the diagnosis and treatment of cancer, and the specificity of tumor cells. The first chapters serve as an introduction to the central topic of this book, targeted therapy. Key aspects of target therapy, such as classes of drugs, immunotherapy, monoclonal antibodies, checkpoint inhibitors, cancer vaccines and tyrosine kinase inhibitors are presented, and, for each one, the benefits, as well as the adverse effects are reported. Chapter 6 compares conventional systemic chemotherapy and targeted therapy, identifies the risks and benefits and also the eligibility criteria for patient care. The possibility of targeted therapy replacing conventional chemotherapy is discussed while reviewing studies that demonstrate the benefits of combining both types of treatment. Finally, the introduction of pharmaceutical nanotechnology to improve antineoplastic agents is addressed in the last chapter and sets the direction for future research in cancer treatment. This is a valuable resource for many health professionals including physicians, pharmacists, nurses, researchers and students interested in the field of oncology.
001434366 588__ $$aOnline resource; title from digital title page (viewed on March 26, 2021).
001434366 650_0 $$aCancer$$xTreatment.
001434366 650_6 $$aCancer$$xTraitement.
001434366 655_0 $$aElectronic books.
001434366 7001_ $$aSoares, José Cleberson Santos,$$eauthor.
001434366 77608 $$iPrint version:$$z3030683338$$z9783030683337$$w(OCoLC)1228318577
001434366 852__ $$bebk
001434366 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-68334-4$$zOnline Access$$91397441.1
001434366 909CO $$ooai:library.usi.edu:1434366$$pGLOBAL_SET
001434366 980__ $$aBIB
001434366 980__ $$aEBOOK
001434366 982__ $$aEbook
001434366 983__ $$aOnline
001434366 994__ $$a92$$bISE